Solentim to Present and Exhibit at the ELRIG “CRISPR in Drug Discovery 2019” Conference in Oxford, UK
NEWS – Bournemouth, 11th February 2019: Solentim, a global leader in cell line development instrumentation, is pleased to announce they will be attending the ELRIG CRISPR in Drug Discovery 2019: From Targets to Therapeutics meeting on the 27-28 February, Oxford, UK.
The meeting will focus on the application of genome engineering to identify novel drug targets through large scale CRISPR-based functional genomics studies, target validation in developing advanced cellular and in vivo disease models, and pioneering applications in therapeutic genome editing. The use of these rapidly developing technologies to further drug discovery research will also be a key point of discussion.
A key consideration when conducting successful CRISPR-based studies is the need to ensure clonally pure cell lines. Technologies such as Solentim’s VIPS & Cell Metric instruments meet this need and are highly applicable for cell engineering and precision gene editing customers (Read more here).
“Gene editing using technologies such as CRISPR/Cas9 is already a powerful and crucial tool in today’s drug discovery pipeline. We are excited to meet with both existing and new customers and collaborators working in this inspiring field, and to broaden the awareness of our tools and applications,” commented Dr Ian Taylor, Chief Commercial Officer for Solentim, who will be attending the conference.
Solentim has been invited to give a short presentation at 12.30pm on 28th February entitled “High-throughput single cell cloning of CRISPR-edited cell lines”, and can be found at Booth #21 throughout the conference.